109903-35-7

Basic information

• Product Name: 4-Amino-N-methylbenzenemethanesulfonamide
• Synonyms: N-Methyl-4-aminobenzenemethanesulfonamide;4-Amino-N-methyl-a-toluenesulfonamide;4-AMINO-N-METHYL-ALPHA-TOLUENESULFONAMI&;4-Aminophenyl-N-MethylMethanesulfonamide(ForSumatriptan);4-Amino-N-methylbenzylsulfonamide;N-Methyl-4-Aminosulfabenzamide;4-amino-n-methyl-à-toluenesulfonamide;4-amino-n-methyl-α-toluenesulfonamide
• CAS NO: 109903-35-7
• Molecular Formula: C₈H₁₂N₂O₂S
• Molecular Weight: 200.26
• EINECS: -0
• Product Categories: Benzene derivates;Building Blocks;Chemical Synthesis;Organic Building Blocks;Sulfonamides/Sulfinamides;Sulfur Compounds
• Mol File: 109903-35-7.mol

Chemical Properties

• Melting Point: 140-142 °C(lit.)
• Boiling Point: 387.6 °C at 760 mmHg
• Flash Point: 188.2 °C
• Appearance: /
• Density: 1.297 g/cm³
• Vapor Pressure: 3.25E-06mmHg at 25°C
• Refractive Index: 1.589
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• PKA: 11.50±0.40(Predicted)
• BRN: 5865321
• CAS DataBase Reference: 4-Amino-N-methylbenzenemethanesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-N-methylbenzenemethanesulfonamide(109903-35-7)
• EPA Substance Registry System: 4-Amino-N-methylbenzenemethanesulfonamide(109903-35-7)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 22-43
• Safety Statements: 36/37
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• HazardClass: 9
• PackingGroup: III
• Hazardous Substances Data: 109903-35-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Amino-N-methylbenzenemethanesulfonamide is used as an intermediate in the synthesis of Sumatriptan (S810000), a medication primarily used to treat migraine headaches. It is particularly effective in alleviating the symptoms of migraines, such as severe headaches, nausea, and sensitivity to light and sound. The compound's role in the synthesis of Sumatriptan highlights its importance in the development of medications for neurological disorders.

InChI:InChI=1/C8H12N2O2S/c1-10-13(11,12)6-7-2-4-8(9)5-3-7/h2-5,10H,6,9H2,1H3

Upstream product

• 85952-29-0 (4-nitro-phenyl)-methanesulfonic acid methylamide 

Relevant articles and documents

INHIBITORS OF PROTEIN KINASES

The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceuticals compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases. formula (I).

Inhibitors of protein kinases

The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceutical compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.

INHIBITORS OF PROTEIN KINASES

The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceuticals compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases. formula (I).

Synthesis of 5-substituted indole derivatives, part II. Synthesis of sumatriptan through the Japp-Klingemann reaction

Synthesis of selective 5-HT(1B/1D) receptor agonist, sumatriptan (1) was accomplished through decarboxylation of 2-carboxy-3-[2-(dimethylamino)ethyl]- N-methyl-1H-indole-5-methanesulfonamide (2) in quinoline with copper powder. The preparation of the acid (2) was effected through the Japp-Klingemann method thus avoiding the need for the formation of hydrazine from diazonium salt. Attempted decarboxylation in N,N-dimethylacetamide resulted in the formation of the β-carboline (16).